These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 8900437)

  • 1. Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells.
    Frisan T; Zhang QJ; Levitskaya J; Coram M; Kurilla MG; Masucci MG
    Int J Cancer; 1996 Oct; 68(2):251-8. PubMed ID: 8900437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
    Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells.
    Khanna R; Cooper L; Kienzle N; Moss DJ; Burrows SR; Khanna KK
    J Immunol; 1997 Dec; 159(12):5782-5. PubMed ID: 9550373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2.
    Lee SP; Thomas WA; Blake NW; Rickinson AB
    Eur J Immunol; 1996 Aug; 26(8):1875-83. PubMed ID: 8765034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.
    Masucci MG; Zhang QJ; Gavioli R; De Campos-Lima PO; Murray RJ; Brooks J; Griffin H; Ploegh H; Rickinson AB
    Int Immunol; 1992 Nov; 4(11):1283-92. PubMed ID: 1282031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line.
    Khanna R; Burrows SR; Argaet V; Moss DJ
    Int Immunol; 1994 Apr; 6(4):639-45. PubMed ID: 7517178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4.
    Levitsky V; Zhang QJ; Levitskaya J; Masucci MG
    J Exp Med; 1996 Mar; 183(3):915-26. PubMed ID: 8642295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway.
    Lautscham G; Mayrhofer S; Taylor G; Haigh T; Leese A; Rickinson A; Blake N
    J Exp Med; 2001 Oct; 194(8):1053-68. PubMed ID: 11602636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells.
    Khanna R; Busson P; Burrows SR; Raffoux C; Moss DJ; Nicholls JM; Cooper L
    Cancer Res; 1998 Jan; 58(2):310-4. PubMed ID: 9443410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of the proteasome inhibitor lactacystin on the presentation of transporter associated with antigen processing (TAP)-dependent and TAP-independent peptide epitopes by class I molecules.
    Bai A; Forman J
    J Immunol; 1997 Sep; 159(5):2139-46. PubMed ID: 9278300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventing vaccinia virus class-I epitopes presentation by HSV-ICP47 enhances the immunogenicity of a TAP-independent cancer vaccine epitope.
    Raafat N; Sadowski-Cron C; Mengus C; Heberer M; Spagnoli GC; Zajac P
    Int J Cancer; 2012 Sep; 131(5):E659-69. PubMed ID: 22116674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt's lymphoma cells. Evidence for a critical role for ICAM-2.
    Khanna R; Burrows SR; Suhrbier A; Jacob CA; Griffin H; Misko IS; Sculley TB; Rowe M; Rickinson AB; Moss DJ
    J Immunol; 1993 Jun; 150(11):5154-62. PubMed ID: 7684421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts.
    Seliger B; Harders C; Lohmann S; Momburg F; Urlinger S; Tampé R; Huber C
    Eur J Immunol; 1998 Jan; 28(1):122-33. PubMed ID: 9485192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.
    Khanna R; Burrows SR; Moss DJ; Silins SL
    J Virol; 1996 Aug; 70(8):5357-62. PubMed ID: 8764046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors.
    Gavioli R; Vertuani S; Masucci MG
    Int J Cancer; 2002 Oct; 101(6):532-8. PubMed ID: 12237893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tap-1 and Tap-2 gene therapy selectively restores conformationally dependent HLA Class I expression in type I diabetic cells.
    Wang F; Li X; Annis B; Faustman DL
    Hum Gene Ther; 1995 Aug; 6(8):1005-17. PubMed ID: 7578413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells.
    Destro F; Sforza F; Sicurella M; Marescotti D; Gallerani E; Baldisserotto A; Marastoni M; Gavioli R
    Immunology; 2011 May; 133(1):105-14. PubMed ID: 21342184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition.
    Lee SP; Constandinou CM; Thomas WA; Croom-Carter D; Blake NW; Murray PG; Crocker J; Rickinson AB
    Blood; 1998 Aug; 92(3):1020-30. PubMed ID: 9680372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma.
    Gavioli R; De Campos-Lima PO; Kurilla MG; Kieff E; Klein G; Masucci MG
    Proc Natl Acad Sci U S A; 1992 Jul; 89(13):5862-6. PubMed ID: 1321426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of an human leucocyte antigen A2-restricted Epstein-Barr virus nuclear antigen-1-derived cytotoxic T-lymphocyte epitope.
    Marescotti D; Destro F; Baldisserotto A; Marastoni M; Coppotelli G; Masucci M; Gavioli R
    Immunology; 2010 Mar; 129(3):386-95. PubMed ID: 19922423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.